Reporting owner · CIK 0001817199

Ring Christine

Visual SEC Form 4 history across 1 companies, 26 transactions and 7 filings.

CLOChief Legal OfficerNurix Therapeutics, Inc.
Open-market mix
Latest filingSep 02, 2026, 11:42 PM
Filings7Form 4 records
Buying$00 purchases
Selling$677.8K8 sales
Net value−$677.8KBuys minus sells
Companies13 securities
Most recentSep 02, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-55Jan 25Feb 251Feb 262Sep 26

Net value flow

Buys minus sells

Jan 25
−$291.2K
Feb 25
$0
Feb 26
−$237.6K
Sep 26
−$149.1K

Transaction texture

Ownership and ticket size

Average P/S size$84.7K
Median P/S size$85.2K
Direct26
Indirect0
Sep 02, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern4Derivative Transactionfiling-context10Direct Ownershipfiling-context22Large Holdings Increaseholdings4Large Holdings Reductionholdings2Large Salesize1Repeat Sellerpattern410b5-1 Detectedfiling-context10

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Nurix Therapeutics, Inc. on Sep 02, 2026 valued at $10,655.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Nurix Therapeutics, Inc. on Sep 02, 2026 valued at $10,655.

Review SEC filing

Associated companies

Visual map of known reporting history

NRIXNurix Therapeutics, Inc.26 transactions · latest Sep 02, 2026, 11:42 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
NRIXRing Christine
CLO
exercise10b5-15.78k$0M
Derivative Transaction Direct Ownership 10b5-1 Detected
0.0%09/0209/02
NRIXRing Christine
CLO
sale10b5-1400-$1.06MS
Cluster Selling Direct Ownership Repeat Seller+1
0.0%09/0209/02
NRIXRing Christine
CLO
sale10b5-15.38k-$13.8MS
Cluster Selling Direct Ownership Large Holdings Reduction+1
0.0%09/0209/02
NRIXRing Christine
CLO
exercise10b5-15.78k$5.04MM
Direct Ownership Large Holdings Increase 10b5-1 Detected
0.0%09/0209/02
NRIXRing Christine
CLO
grant42.8k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
−1.0%02/1002/10
NRIXRing Christine
CLO
grant93.7k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
−1.0%02/1002/10
NRIXRing Christine
CLO
sale10b5-114.2k-$23.7MS
Direct Ownership Large Holdings Reduction Large Sale+1
−1.0%02/1002/09
NRIXRing Christine
CLO
grant34.3k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—02/13/202502/11/2025
NRIXRing Christine
CLO
grant75.0k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—02/13/202502/11/2025
NRIXRing Christine
CLO
exercise10b5-15.53k$0M
Derivative Transaction Direct Ownership 10b5-1 Detected
—02/04/202501/31/2025

Ring Christine Insider Activity FAQ

SEC Form 4 context

Who is Ring Christine?

Ring Christine is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001817199.

Which companies has Ring Christine reported transactions for?

Nurix Therapeutics, Inc.

When was Ring Christine's latest insider buy?

No open-market insider purchase is available for this period.

When was Ring Christine's latest insider sale?

sale at Nurix Therapeutics, Inc. on Sep 02, 2026 valued at $10,655.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.